Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection

• DOI: 10.1111/cmi.12608
• Publication Date: 2016-05-01T10:48:04Z
• Authors: Kaitian Peng; Yun Shan Goh; Anthony Siau; Jean-François Fra...; Wan Ni Chia; Alice Soh Meoy Ong; Benoit Malleret; Ying Ying Wu; Georges Snounou; Cornelus C. Hermsen; John H. Adams; Dominique Mazier; Peter R. Preiser; Robert W. Sauerwein; Anne-Charlotte Gr...; Laurent Rénia
• Keywords: Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences; 0301 basic medicine; Immune Sera; Plasmodium falciparum; Vaccination; Protozoan Proteins; Antibodies, Protozoan; Gene Expression; Antigens, Protozoan; Chloroquine; Receptors, Cell Surface; Cross Reactions; Antibodies, Neutralizing; Immunity, Humoral; 3. Good health; Antimalarials; 03 medical and health sciences; Peptide Library; Sporozoites; Malaria Vaccines; Hepatocytes; Animals; Humans; Malaria, Falciparum

The development of an effective malaria vaccine has remained elusive even until today. This is because our incomplete understanding the immune mechanisms that confer and/or correlate with protection. Human volunteers have been protected experimentally from a subsequent challenge by immunization Plasmodium falciparum sporozoites under drug cover. Here, we demonstrate sera individuals contain neutralizing antibodies against pre-erythrocytic stage. To identify antigen(s) recognized these antibodies, newly developed library P. antigens was screened sera. Antibodies broad antigenic repertoire which three antigens, PfMAEBL, PfTRAP and PfSEA1 were most individuals. As proof principle, demonstrated anti-PfMAEBL block liver stage in human hepatocytes. Thus, identified are promising targets for malaria.